Ginkgo Biloba: Does It Really Improve Cognitive Function? | Cochrane Review Findings

Recent research reinforces a nuanced understanding of Ginkgo biloba’s effects on cognitive function. A comprehensive Cochrane Review, analyzing data from 82 placebo-controlled trials, indicates that Ginkgo biloba extract doesn’t demonstrate measurable benefits for individuals experiencing mild cognitive impairment (MCI). Yet, the review suggests a potential, though limited, positive impact on cognition and daily functioning in people diagnosed with dementia. This finding underscores the importance of evidence-based approaches when considering complementary therapies for cognitive health.

Understanding Mild Cognitive Impairment and Dementia

Mild cognitive impairment (MCI) represents a stage between normal age-related cognitive decline and dementia. Individuals with MCI may experience noticeable problems with memory, language, or thinking, but these issues generally don’t interfere significantly with daily life. Dementia, is a more severe syndrome characterized by a significant decline in cognitive abilities that impacts independence and daily activities. Alzheimer’s disease is the most common form of dementia, but vascular dementia and mixed types also occur. The Cochrane review highlights the critical distinction between these conditions when evaluating potential treatments.

The Cochrane Review: A Deep Dive into the Evidence

The Cochrane Review, published in February 2026, synthesized findings from a substantial body of research. Researchers meticulously examined randomized controlled trials (RCTs) comparing Ginkgo biloba to placebo, standard care, or other treatments in individuals with cognitive complaints, MCI, or dementia. The analysis focused on key outcomes measured at six months, including overall clinical status, global cognitive function, activities of daily living, and adverse events. The review included data up to November 2024, building on previous analyses. As detailed in PubMed, the objective was to rigorously assess both the potential benefits and harms associated with Ginkgo biloba use.

What the Findings Indicate for Those with MCI

For individuals experiencing MCI, the Cochrane Review provides relatively clear guidance: Ginkgo biloba is unlikely to offer significant cognitive benefits. The studies included in the review did not demonstrate a consistent or meaningful improvement in overall condition, thinking skills, or the ability to perform everyday tasks compared to a placebo. This doesn’t necessarily mean Ginkgo biloba is harmful, but it suggests that relying on it as a primary intervention for MCI is not supported by current evidence. It’s important to remember that no currently available treatments have been proven to halt or slow the progression of MCI. Management typically focuses on lifestyle modifications, cognitive training, and addressing underlying health conditions.

A More Complex Picture for Dementia

The results for individuals with dementia are more ambiguous. The review suggests that Ginkgo biloba may offer some benefit in improving overall condition, cognitive function, and daily living skills. However, the researchers emphasize that the findings across individual studies were quite variable. This inconsistency makes it difficult to draw firm conclusions about the magnitude of the effect. The review notes that while some studies showed positive results, others did not, and the observed benefits were often modest. Further investigation is needed to determine which individuals with dementia might be most likely to respond to Ginkgo biloba, and at what dosage.

Safety Considerations and Potential Risks

Importantly, the review found no evidence of increased harm associated with Ginkgo biloba use in individuals with either MCI or dementia. However, it’s crucial to acknowledge that this doesn’t mean Ginkgo biloba is entirely without risk. Like any herbal supplement, it can interact with certain medications, such as blood thinners, potentially increasing the risk of bleeding. Individuals considering Ginkgo biloba should always discuss it with their healthcare provider, especially if they have pre-existing medical conditions or are taking other medications. The review did not assess long-term safety, so the potential for delayed or less common adverse effects remains uncertain.

The Importance of Context: Relative vs. Absolute Risk

When interpreting research findings, it’s essential to understand the difference between relative and absolute risk. A study might report a statistically significant relative risk reduction, which sounds impressive, but the actual absolute benefit might be slight. For example, a 20% relative risk reduction in cognitive decline might translate to only a modest improvement in cognitive scores over six months. The Cochrane Review’s emphasis on the variability of results across studies highlights this point. The observed benefits of Ginkgo biloba, when present, appear to be relatively small and may not be clinically meaningful for all individuals.

What’s Next: Ongoing Research and Clinical Practice

The Cochrane Review underscores the need for continued research into the potential role of Ginkgo biloba in cognitive health. Future studies should focus on identifying subgroups of individuals with dementia who might be more likely to benefit from the supplement, exploring optimal dosages, and investigating long-term safety. Researchers are also exploring other potential interventions for cognitive impairment and dementia, including lifestyle modifications, cognitive training, and novel pharmacological approaches. For clinicians, the review reinforces the importance of a comprehensive assessment of cognitive function and individualized treatment plans based on the best available evidence. Regular reviews of the evidence, like those conducted by Cochrane, are crucial for updating clinical guidelines and ensuring that patients receive the most appropriate care.